Juniper Biologics Pte. Ltd. has added another candidate to its pipeline in the space of less than a month. In the latest deal, the Singapore-based company inked an exclusive licensing agreement with Switzerland’s Helsinn Healthcare SA, gaining rights to develop and commercialize oncology drug infigratinib in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.
Tumor infiltrating lymphocyte (TIL) therapy is a promising approach to cancer cell therapy that could provide a new option for people whose cancers have not responded to previous lines of treatment – and Denmark’s Cbio A/S is heading to the clinic with a new contender in the field. Delegates at the Anglonordic Life Science Conference in London, held on May 5, heard from CEO Ulrik Cordes, who explained the company aims to outperform rivals from Iovance Biotherapeutics Inc. and Instil Bio Inc. with its proprietary approach to TIL.
As the American Society of Clinical Oncology meeting nears, presenters are talking up their prospects, including Biomea Fusion Inc. with early data from experiments testing BMF-219, an oral, irreversible covalent menin inhibitor – one in an intriguing class that has sparked efforts by various developers.
There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.
RSS
